RA Capital Management 13F holdings, Q3 2022
Holdings as of September 30, 2022 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 81 US equity positions worth $4.7bn in its Q3 2022 13F filing. The largest position was ASND at 16.7% of the reported book, followed by BIIB and CTKB. Against the Q2 2022 filing, it opened 7 new positions, added to 7 and reduced 0 among the top 50 holdings.
What did RA Capital Management own in Q3 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2022 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 16.7% | $781.5m | 7,567,900 | 0% | held |
| 2 | BIIB BIOGEN INC | Healthcare | 5.3% | $250.3m | 937,549 | 29% | added |
| 3 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 4.2% | $197.0m | 13,381,054 | 0% | held |
| 4 | FORMA THERAPEUTICS HLDGS INC | 3.8% | $179.8m | 9,011,651 | 0% | held | |
| 5 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 3.0% | $141.0m | 7,040,622 | 0% | held | |
| 6 | AEROVATE THERAPEUTICS INC | 2.9% | $137.0m | 8,263,982 | 0% | held | |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.9% | $134.0m | 5,471,067 | 12% | added |
| 8 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 2.6% | $121.3m | 4,922,941 | 0% | held |
| 9 | BELLUS HEALTH INC NEW | 2.6% | $120.2m | 11,385,574 | 11% | added | |
| 10 | JANX JANUX THERAPEUTICS INC | Healthcare | 2.5% | $117.4m | 8,670,644 | 0% | held |
| 11 | PCVX VAXCYTE INC | Healthcare | 2.3% | $109.9m | 4,581,203 | 0% | held |
| 12 | DICE THERAPEUTICS INC | 2.3% | $105.6m | 5,208,911 | 0% | held | |
| 13 | IMMUNOGEN INC | 2.2% | $103.9m | 21,741,458 | 0% | held | |
| 14 | NKTX NKARTA INC | Healthcare | 2.2% | $102.7m | 7,805,129 | 0% | held |
| 15 | ABOS ACUMEN PHARMACEUTICALS INC | 2.1% | $98.0m | 9,770,773 | 0% | held | |
| 16 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.0% | $95.4m | 2,338,610 | – | new |
| 17 | ITEOS THERAPEUTICS INC | 1.8% | $84.1m | 4,417,259 | 0% | held | |
| 18 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.6% | $74.0m | 2,000,000 | 0% | held |
| 19 | PEPG PEPGEN INC | Healthcare | 1.6% | $73.8m | 8,131,952 | 0% | held |
| 20 | GERN GERON CORP | Healthcare | 1.5% | $70.5m | 30,126,299 | 0% | held |
| 21 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 1.5% | $69.2m | 4,398,453 | 0% | held |
| 22 | THIRD HARMONIC BIO INC | 1.4% | $65.9m | 3,475,687 | – | new | |
| 23 | ANTX AN2 THERAPEUTICS INC | 1.4% | $65.6m | 3,773,517 | 1% | added | |
| 24 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.4% | $63.6m | 7,236,454 | 0% | held |
| 25 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.3% | $62.1m | 17,202,009 | 0% | held |
| 26 | VRNA VERONA PHARMA PLC | 1.3% | $61.8m | 6,050,000 | 19% | added | |
| 27 | COGT COGENT COMMUNICATIONS HLDGS | Healthcare | 1.3% | $59.9m | 4,013,453 | – | new |
| 28 | NANOSTRING TECHNOLOGIES | 1.3% | $58.8m | 4,602,478 | 28% | added | |
| 29 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.2% | $58.3m | 2,075,000 | 0% | held |
| 30 | GHRS GH RESEARCH PLC | 1.2% | $56.9m | 4,898,373 | 0% | held | |
| 31 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.2% | $56.6m | 7,000,000 | – | new |
| 32 | KINNATE BIOPHARMA INC | 1.1% | $51.0m | 4,264,144 | 0% | held | |
| 33 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 1.0% | $46.5m | 896,724 | 0% | held |
| 34 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 1.0% | $46.4m | 2,773,231 | 27% | added |
| 35 | 89BIO INC | 1.0% | $45.1m | 7,782,669 | 0% | held | |
| 36 | VOR VOR BIOPHARMA INC | 0.9% | $44.3m | 11,120,973 | 0% | held | |
| 37 | CLYM ELIEM THERAPEUTICS INC | 0.9% | $42.5m | 13,150,849 | 0% | held | |
| 38 | TIL INSTIL BIO INC | 0.8% | $37.1m | 7,670,793 | 0% | held | |
| 39 | RXST RXSIGHT INC | Healthcare | 0.8% | $36.6m | 3,052,796 | 0% | held |
| 40 | SATSUMA PHARMACEUTICALS INC | 0.8% | $35.5m | 5,914,252 | 0% | held | |
| 41 | AVIDITY BIOSCIENCES INC | 0.8% | $35.4m | 2,167,391 | 0% | held | |
| 42 | VERA VERA THERAPEUTICS INC | Healthcare | 0.7% | $33.6m | 1,578,820 | 0% | held |
| 43 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.7% | $33.6m | 2,107,149 | 0% | held |
| 44 | AKERO THERAPEUTICS INC | 0.7% | $32.7m | 958,980 | – | new | |
| 45 | ALPINE IMMUNE SCIENCES INC | 0.7% | $31.4m | 4,356,632 | – | new | |
| 46 | HILLEVAX INC | 0.6% | $30.1m | 1,760,019 | 0% | held | |
| 47 | ACET ADICET BIO INC | Healthcare | 0.6% | $29.3m | 2,059,372 | – | new |
| 48 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 0.6% | $26.7m | 3,370,506 | 0% | held |
| 49 | MILESTONE PHARMACEUTICALS IN | 0.4% | $20.6m | 2,246,503 | 0% | held | |
| 50 | PMVP PMV PHARMACEUTICALS INC | 0.4% | $20.4m | 1,710,265 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.